Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106923 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02106923 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 72 participants.
The verdict
NCT02106923, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
Interventions
- DRUG 1 tablet Empagliflozin/2 tablets Metformin XR
- DRUG 10 mg Empagliflozin/1000 mg Metformin XR
- DRUG 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
- DRUG 2 tablets 5 mg Empagliflozin/750 Metformin XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106923
The ClinicalTrials.gov registry entry for NCT02106923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 1 tablet Empagliflozin/2 tablets Metformin XR is the first listed.
NCT02106923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106923 about?
NCT02106923 is a clinical study titled "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets". The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
What is the current status of trial NCT02106923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2014-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02106923?
The interventions under investigation include: 1 tablet Empagliflozin/2 tablets Metformin XR (DRUG), 10 mg Empagliflozin/1000 mg Metformin XR (DRUG), 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR (DRUG), 2 tablets 5 mg Empagliflozin/750 Metformin XR (DRUG).
Who is sponsoring clinical trial NCT02106923?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.